A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma. Tumor microenvironment signals and circulating factors may jointly ...

At a median follow-up of 67.6 months, patients who received nivolumab and cabozantinib had continued improvements in response and survival outcomes. Combination treatment with nivolumab and ...

Nivolumab/cabozantinib showed superior progression-free and overall survival compared to sunitinib in advanced RCC, with a median follow-up of 67.6 months. The combination therapy demonstrated higher ...

Boston – Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium, on February 13-15, 2025, in San Francisco, Calif.

Source: Getty Images Researchers provided recommendations for managing hypertension, diarrhea, palmar-plantar erythrodysesthesia, and liver enzyme elevations in patients with renal cell carcinoma ...

Over the 48-month period following random assignment, patients in the intention-to-treat (ITT) population who received the combination (n = 323) experienced a mean TFS of 7.0 months compared with 4.6 ...

Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell ...

Five years after scoring an FDA approval to treat newly diagnosed advanced kidney cancer, the combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta has failed on the overall survival endpoint of a ...

Bristol Myers Squibb & Co (NYSE:BMY) and Exelixis Inc (NASDAQ:EXEL) revealed four-year follow-up results from a cancer study that compared one treatment with another from Pfizer Inc (NYSE:PFE). What ...

Opdivo in combination with CABOMETYX reduced the risk of death by 23% in the first-line treatment of advanced renal cell carcinoma vs. sunitinib Four-year results demonstrating continued benefits with ...

First presentation of results from Phase 3 CheckMate -67T trial with subcutaneous formulation of Opdivo (nivolumab and hyaluronidase) to be shared in a late-breaking oral presentation Four-year data ...